ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection [abstract 253] | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection [abstract 253]

Zeuzem S, Feld J, Wang S. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection [abstract 253]. In The Liver Meeting 2016. Boston, MA; 2016.

Publication Type:

Conference Paper

Authors:

Zeuzem, Stefan; Feld, Jordan; Wang, Stanley

Source:

The Liver Meeting 2016, Boston, MA (2016)

Cited On:

Export Citation:

RIS Format

Top